Preclinical evidence of IGF1R/IR pathway inhibition in combination with GD2-CAR T-cells as a potent therapeutic strategy for diffuse midline glioma H3K27M mutant

This webinar explores the potential use of GD2-CAR T-cells as a therapeutic strategy in treating aggressive pediatric brain tumors that have a poor prognosis and limited treatment options: Diffuse midline gliomas (DMG) H3K27M mutant, including diffuse intrinsic pontine glioma (DIPG). Dr. Maria Vinci and the team at Bambino Gesù Children’s Hospital, in Italy, have developed a high-throughput cell-based assay where they screened 42 kinase inhibitors in combination with GD2-CAR T-cells. They identified two dual IGF1R/IR antagonists, BMS-754807 and linsitinib, both which were able to inhibit tumor cell viability at concentrations that did not affect CAR T-cells.

Key learning objectives

• Learn how GD2-CAR T-cells can be used as a therapeutic strategy against aggressive pediatric brain tumors
• Gain insight into the development of a high-throughput cell-based assay to screen 42 kinase inhibitors
• Understand how the enhanced anti-tumor activity of the linsitinib/GD2-CAR T-cell combination strategy was confirmed in DIPG models using 3D cultures in vitro, organotypic brain slices ex vivo, and an orthotopic xenograft model of DIPG in vivo.

Who should attend?

• Director, formulation development, cell and gene therapy product development
• Scientist, gene editing
• Associate scientist, gene and cell therapy, discovery research
• Research associate, cell and gene therapy
• Department Head, non-viral gene therapy
• VP, cell and gene therapy development
• Cell therapy associate, science & technology
• Senior scientist, virology – gene therapy
• Chemistry, Manufacturing, and Control (CMC) gene therapy
• CMC cell and gene therapy
• Head of Good Laboratory Practice (GLP) studies, gene therapy
• Product quality lead, cell and gene therapy

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.